Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) dropped 5.3% during mid-day trading on Monday . The company traded as low as $15.99 and last traded at $16.31. Approximately 92,916 shares traded hands during trading, a decline of 49% from the average daily volume of 183,939 shares. The stock had previously closed at $17.22.
Analyst Ratings Changes
SION has been the topic of a number of research reports. Guggenheim began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating and a $45.00 price target on the stock. Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $32.00 price target on the stock. TD Cowen started coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating on the stock. Finally, Wall Street Zen downgraded Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.
Get Our Latest Stock Report on Sionna Therapeutics
Sionna Therapeutics Stock Down 1.6%
The stock's fifty day simple moving average is $12.54.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Institutional Trading of Sionna Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the company. TD Asset Management Inc purchased a new stake in Sionna Therapeutics during the 1st quarter worth $579,000. Goldman Sachs Group Inc. bought a new position in shares of Sionna Therapeutics during the first quarter worth about $667,000. Charles Schwab Investment Management Inc. bought a new position in shares of Sionna Therapeutics during the first quarter worth about $676,000. Woodline Partners LP acquired a new stake in Sionna Therapeutics during the first quarter worth about $837,000. Finally, CenterBook Partners LP acquired a new stake in Sionna Therapeutics during the first quarter worth about $1,195,000.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
